PRODUCT DEFECT CORRECTION - PALEXIA® SR 100mg

In consultation with the Therapeutic Goods Administration (TGA), Seqirus is issuing a Product Defect Correction for PALEXIA® SR 100mg tablet lot 985P01.

news

This Product Defect Correction has been initiated as a precautionary measure after a single report of missing product information on the blister foil. It is important to note that there is no impact to the actual working of the medicine.

This correction does not affect any other lots or presentations of PALEXIA® or any other Seqirus products.

Customers and pharmacists are requested to inspect the product prior to use or dispensing. Customers should return any affected product to the point of purchase.

This Product Defect Correction only applies to product missing information on the blister foil. It does not apply to product with the complete print on the blister foil.

Seqirus apologises for any inconvenience caused – our customer service team can be contacted on 1800 008 275.